Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian

por Kanefendt, Friederike, Brase, Christine, Unger, Sigrun, Kubitza, Dagmar
Publicado 2022

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

por Thomas, Dirk, Kanefendt, Friederike, Schwers, Stephan, Unger, Sigrun, Yassen, Ashraf, Boxnick, Stefanie
Publicado 2021

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

por Kubitza, Dagmar, Heckmann, Michael, Distler, Jana, Koechel, Annemone, Schwers, Stephan, Kanefendt, Friederike
Publicado 2022

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans

por Piel, Isabel, Engelen, Anna, Lang, Dieter, Schulz, Simone I., Gerisch, Michael, Brase, Christine, Janssen, Wiebke, Fiebig, Lukas, Heitmeier, Stefan, Kanefendt, Friederike
Publicado 2023